• About
  • Advertise
  • Privacy & Policy
  • Contact
Tech News, Magazine & Review WordPress Theme 2017
  • Home
  • Gaming

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    National Academy of Sciences endorses embryonic engineering

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    The Analogue Nt Mini is the perfect NES console for video game lovers

    GoPro’s Karma drone is back on sale after design flaw made them fall out of the sky

  • Gear
    • All
    • Audio
    • Camera
    • Laptop
    • Smartphone

    Apple Watch Series 2 Is Swimproof and Comes With Built-In GPS

    National Academy of Sciences endorses embryonic engineering

    Jack Dorsey says he’ll continue running both Square and Twitter

    Fujifilm X-T2 review: The definition of a great camera

    The Warby Parker of hair color, Madison Reed, scores new funding and a CMO

    Shopify CEO attempts to defend continued hosting of Breitbart’s online store

    Trending Tags

    • Best iPhone 7 deals
    • Apple Watch 2
    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • iOS 10
    • iPhone 7
    • Sillicon Valley
  • Computers

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    Fujifilm X-T2 review: The definition of a great camera

    Shopify CEO attempts to defend continued hosting of Breitbart’s online store

    SpaceX targets February 18 for Dragon resupply mission to ISS

  • Applications

    Apple Watch Series 2 Is Swimproof and Comes With Built-In GPS

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    National Academy of Sciences endorses embryonic engineering

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    Jack Dorsey says he’ll continue running both Square and Twitter

  • Security

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    National Academy of Sciences endorses embryonic engineering

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    The Warby Parker of hair color, Madison Reed, scores new funding and a CMO

    Shopify CEO attempts to defend continued hosting of Breitbart’s online store

No Result
View All Result
  • Home
  • Gaming

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    National Academy of Sciences endorses embryonic engineering

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    The Analogue Nt Mini is the perfect NES console for video game lovers

    GoPro’s Karma drone is back on sale after design flaw made them fall out of the sky

  • Gear
    • All
    • Audio
    • Camera
    • Laptop
    • Smartphone

    Apple Watch Series 2 Is Swimproof and Comes With Built-In GPS

    National Academy of Sciences endorses embryonic engineering

    Jack Dorsey says he’ll continue running both Square and Twitter

    Fujifilm X-T2 review: The definition of a great camera

    The Warby Parker of hair color, Madison Reed, scores new funding and a CMO

    Shopify CEO attempts to defend continued hosting of Breitbart’s online store

    Trending Tags

    • Best iPhone 7 deals
    • Apple Watch 2
    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • iOS 10
    • iPhone 7
    • Sillicon Valley
  • Computers

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    Fujifilm X-T2 review: The definition of a great camera

    Shopify CEO attempts to defend continued hosting of Breitbart’s online store

    SpaceX targets February 18 for Dragon resupply mission to ISS

  • Applications

    Apple Watch Series 2 Is Swimproof and Comes With Built-In GPS

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    National Academy of Sciences endorses embryonic engineering

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    Jack Dorsey says he’ll continue running both Square and Twitter

  • Security

    To regain advertiser trust, Facebook is tracking ads by the millisecond

    National Academy of Sciences endorses embryonic engineering

    Google has been asked to take down over a million websites

    Watch Dogs 2 Update Coming This Week, Here’s What It Does

    The Warby Parker of hair color, Madison Reed, scores new funding and a CMO

    Shopify CEO attempts to defend continued hosting of Breitbart’s online store

No Result
View All Result
Desknery News
No Result
View All Result

Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases

developer1 by developer1
August 24, 2020
Home Education
Share on FacebookShare on Twitter
0 0
Read Time:5 Minute, 17 Second

NEW YORK and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent for methods and use of fully human monoclonal antibody (mAb; TZLS-501) that recognizes both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases. The Company initially entered into a world-wide exclusive license from Novimmune, SA., a Swiss Biotechnology company in 2017. The license is currently maintained with Bristol Myers Squibb. The patent (No. 10,759,862) will be published by the USPTO on September 1, 2020. The grant of this additional patent on TZLS-501 is of particular significance for the potential treatment of COVID-19 and other pulmonary diseases such as acute respiratory distress syndrome (ARDS). 

The major distinguishing feature of TZLS-501 is that it acts via a dual mechanism by not only inhibiting IL-6R signaling but also depleting circulating levels of IL-6. This distinctive feature of TZLS-501, a fully human anti-IL-6R mAb, makes it potentially suitable for treatment of COVID-19 and ARDS.  For example, COVID-19 patients often develop an uncontrolled immune response (“cytokine storm”) resulting in severe damage to the lung tissue which could lead to respiratory failure. Many studies have also indicated excessive levels of IL-6 in the lungs and in the blood of these patients, and it is believed that the cytokine storm in lungs is primarily due to excessive levels of IL-6. Hence, direct inhalation delivery of TZLS-501 to the lungs using a hand-held nebulizer has the potential to deplete circulating levels of IL-6 and inhibit IL-6R signaling thus providing immediate relief to COVID-19 patients. 

“The granting of this patent along with our previously filed patent application on inhalation delivery of anti-IL-6 mAbs strengthens our intellectual property for the treatment of lung diseases. We are expediting the clinical development of TZLS-501, GMP manufacturing, simultaneously developing inhalation delivery directly to the lungs using a nebulizer and conducting the inhalation safety toxicology studies in Cynomolgus monkeys. Completion of these studies will enable us to file an IND and initiate a clinical trial in COVID-19 patients by Q1 2021. Subsequently, we plan to use TZLS-501 with the same inhalation delivery technology for the treatment of patients with ARDS”, added Dr. Kunwar Shailubhai, CEO & CSO of Tiziana.

The person who arranged for the release of this announcement on behalf of the Company was Dr Kunwar Shailubhai, CEO & CSO of Tiziana.

About TZLS-501
TZLS-501, a fully human mAb, was acquired from Novimmune, SA, a Swiss biotechnology company, in 2017. The cytokine, IL-6, a major determinant in the priming of pathogenic T cells to produce an inflammatory response, binds to its receptor subunit IL-6Rα on the cell membrane. The receptor IL-6Rα can be shed in soluble form, sIL6Rα, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this complex mediates pro-inflammatory effects underlying inflammatory diseases such as rheumatoid arthritis (RA) and acute respiratory distress syndrome (ARDS). The Company believes that the features of TZLS-501 consisting of its dual mechanism of action to inhibit signaling by the membrane-bound and soluble IL-6 receptor and the rapid depletion of circulating IL-6 cytokines, a major cause of lung damage, suggests a potential role for TZLS-501 in patient management and treatment of COVID-19.

About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIM: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation, and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of hospitalized COVID-19 patients with severe respiratory symptoms.

Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries:
United Kingdom:

Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
+44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner
+44 (0)20 7213 0880
Optiva Securities Limited (Broker)
Robert Emmet

United States:
Investors
Dave Gentry
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

Share

Facebook
Twitter
Pinterest
LinkedIn

About Post Author

developer1

abdullah@evertise.net
Happy
Happy
0 0 %
Sad
Sad
0 0 %
Excited
Excited
0 0 %
Sleepy
Sleepy
0 0 %
Angry
Angry
0 0 %
Surprise
Surprise
0 0 %
developer1

developer1

Next Post

INX Limited Announces Effectiveness of Security Token IPO

Recommended.

BLU ANNOUNCES KICKSTARTER CAMPAIGN AND DEMO RELEASE

April 6, 2021

THE INVESTORS COLISEUM WELCOMES PETROLYMPIC LTD. TO ITS WEBSITE AS A FEATURED COMPANY

March 30, 2021

Trending.

Heal Yourself with the Help of Daniel the Healer

Heal Yourself with the Help of Daniel the Healer

January 4, 2023
Five biggest hacks in the history of the Cyber Security

Five biggest hacks in the history of the Cyber Security

January 26, 2023
Desknery News

© 2022 Desknery - All rights reserved.

Quick Links

  • About
  • Advertise
  • Privacy & Policy
  • Contact

Follow Us

No Result
View All Result
  • Home
  • Gaming
  • Gear
  • Computers
  • Applications
  • Security

© 2022 Desknery - All rights reserved.